TD2 and Critical Outcome Technologies develop novel anti-cancer drug
Tuesday, January 12, 2010 - 13:07
in Health & Medicine
TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.